¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"extractable nuclear antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • epithelial membrane antigen
    »óÇǸ·Ç׿ø
  • fimbrial antigen
    °¡´ÂÅÐÇ׿ø
  • flagellar antigen
    Æí¸ðÇ׿ø
  • formalinized antigen
    Æ÷¸£¸»¸°Ã³¸®Ç׿ø
  • functional antigen
    ±â´ÉÇ׿ø
  • granulocyte-erythrocyte antigen
    °ú¸³±¸ÀûÇ÷±¸Ç׿ø
  • granulocyte-monocyte antigen
    °ú¸³±¸´ÜÇÙ±¸Ç׿ø
  • granulocyte-specific antigen
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • group antigen
    ¹«¸®Ç׿ø, ±ºÇ׿ø
  • group-specific antigen
    ¹«¸®Æ¯ÀÌÇ׿ø, ±ºÆ¯ÀÌÇ׿ø
  • hepatitis B core antigen
    BÇü°£¿°ÇÙ½ÉÇ׿ø
  • hepatitis B surface antigen
    BÇü°£¿°Ç¥¸éÇ׿ø
  • heterogenetic antigen
    ÀÌÁ¾Ä£È­Ç׿ø
  • heterophil antigen
    ÀÌÁ¾Ä£È­Ç׿ø
  • hidden antigen
    ¼ûÀºÇ׿ø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • egg antigen
    Ãæ¶õÇ׿ø
  • envelope antigen
    ¿ÜÇÇÇ׿ø
  • environmental antigen
    ȯ°æÇ׿ø
  • excretory-secretory antigen
    ºÐºñ¹è¼³Ç׿ø
  • fimbrial antigen
    °¡´ÂÅÐÇ׿ø
  • flagellar antigen
    ±äÅÐÇ׿ø
  • formalinized antigen
    Æ÷¸£¸»¸°Ã³¸®Ç׿ø
  • functional antigen
    ±â´ÉÇ׿ø
  • granulocyte-erythrocyte antigen
    °ú¸³±¸ÀûÇ÷±¸Ç׿ø
  • granulocyte-monocyte antigen
    °ú¸³±¸´ÜÇÙ±¸Ç׿ø
  • granulocyte-specific antigen
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • group antigen
    ±ºÇ׿ø
  • group-specific antigen
    ±ºÆ¯ÀÌÇ׿ø
  • hepatitis B core antigen
    ºñÇü°£¿°ÇÙ½ÉÇ׿ø
  • hepatitis B surface antigen
    ºñÇü°£¿°Ç¥¸éÇ׿ø
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • P antigen
    P Ç׿ø
  • P-24 antigen
    P-24 Ç׿ø
  • Pr antigen
    Pr Ç׿ø
  • Qa antigen
    QaÇ׿ø (H-2º¹ÇÕüÀÇ)
  • Rh(D) antigen
    Rh(D) Ç׿ø
  • Ro antigen
    RoÇ׿ø
  • Ro antigen
    Ro Ç׿ø
  • Roger antigen
    ·ÎÀúÇ׿ø
  • Scianna antigen
    ½Ã¾Æ³ªÇ׿ø
  • Sda antigen
    Sda Ç׿ø
  • Sp (Pr) antigen
    Sp(Pr) Ç׿ø
  • T dependent antigen
    TÀÇÁ¸¼ºÇ׿ø
  • Tac antigen
    Tac Ç׿ø
  • Thy-1 antigen
    Thy-1Ç׿ø
  • U antigen
    U Ç׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • nuclear saccule
    ÇÙÁÖ¸Ó´Ï
  • nuclear sclerosis
    ¼öÁ¤Ã¼ÇÙ°æÈ­
  • nuclear sclerosis cataract
    ÇÙ°æÈ­¹é³»Àå
  • nuclear segmentation
    (¼¼Æ÷)Çٺп­(á¬øàú·ÝÂæñ).
  • nuclear sex
    ÇÙ¼ºº°(ú·àõܬ).
  • nuclear shift
    ÇÙÀ̵¿(Ì´ËöËÄ) ¹éÇ÷±¸ÀÇ .
  • nuclear spin
    ÇÙ ½ºÇÉ
  • nuclear spindle =nucleospindle
    ÇÙ¹æÃß (ú·Û·õß).
  • nuclear stain
    ÇÙ¿°·á, (Á¶Á÷)ÇÙ¿°»ö(ðÚòÄú· æøßä).
  • nuclear stain
    ÇÙ¿°·á, (Á¶Á÷)ÇÙ¿°»ö(ðÚòÄú·æøßä)
  • nuclear staining
    ÇÙ¿°»ö.
  • nuclear staining
    ÇÙ¿°»ö(ú·æøßä)
  • nuclear structure
    ÇÙ±¸Á¶
  • nuclear vesicle
    ÇÙ¼ÒÆ÷
  • nuclear ³ª nuclearis
    ÇÙÀÇ »ý¹°ÀÇ , ¿øÀÚÇÙ (ê«í­ú·)ÀÇ.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
LFA left femoral artery; left frontal craniotomy; left fronto-anterior [fetal position]; leukocyte funct...
MSA major serologic antigen; male-specific antigen; mannitol salt agar; Medical Services Administration;...
PA panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'...
SSAA sicca syndrome associated antigen A; Sjogren syndrome-associated antigen A; syringomyelia secondary ...
TA alkaline tuberculin; arterial tension; axillary temperature; tactile afferent; Takayasu arteritis; t...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
RANA rheumatoid arthritis nuclear antigen
T-antigen Thomsen Friedenreich antigen
T-antigen Tumor antigen
(1)H-NMR 1)H-nuclear magnetic resonance
NMR 1)H-nuclear magnetic resonance
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
U1 small nuclear RNA-(guanosine-N2)-methyltransferase <enzyme> A trans-active non-small nuclear ribonucleoprotein; facilitates the formation of the m3g cap
Registry number: EC 2.1.1.-
Synonym: u1 snrna(g-n2)mtase
(26 Jun 1999)
U6 small nuclear RNA methyltransferase <enzyme> Methylates gamma-phosphate residues in rnas; distinct from u6 snrna n6-adenosine methyltranferase; mw 130 kD; from hela cells
Registry number: EC 2.1.1.-
Synonym: u6 snrna capping enzyme
(26 Jun 1999)
acetone-insoluble antigen A diphosphatidyl glycerol that is found in the membrane of Treponema pallidum and is the antigen detected by the Wasserman test for syphilis.
(18 Nov 1997)
allogeneic antigen Genetic variations of the same antigens within a given species.
(05 Mar 2000)
antigen Virus coded cell surface antigens that appear soon after the infection of a cell by virus, but before virus replication has begun.
See: early gene.
(18 Nov 1997)
antigen-antibody complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble.
Immune complexes activate complement through the classical pathway.
See: glomerulonephritis, Arthus reaction, type III hypersensitivity.
(12 Dec 1998)
antigen-antibody reaction The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin.
See: skin test.
(05 Mar 2000)
antigen-binding site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
antigen-combining site See: paratope.
(05 Mar 2000)
antigen excess In a precipitation test, the presence of uncombined antigen above that required to combine with all of the antibody; precipitation may be inhibited because the presence of excess antigen gives rise to soluble antigen-antibody complexes, in vivo the resultant antigen-antibody interaction in such an antigen excess may give rise to immune complexes, which have a potential to induce cellular damage; such injury underlies the pathologic changes seen in certain immune complex diseases.
(05 Mar 2000)
antigen interferon <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation.
This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity.
Synonym: antigen interferon, immune interferon.
Pharmacological action: antineoplastic agent, antiviral agents.
(20 Sep 2002)
antigen p150,95 A major adhesion-associated heterodimer molecule expressed by human monocytes, granulocytes, nk cells, and some lymphocytes. The alpha subunit is the CD11c antigen (also called leu-m5), a surface antigen expressed on some myeloid cells. The beta subunit is the CD18 antigen (antigens, CD18). The p150,95 antigen has been shown to play an important role in cell-cell and cell-substrate adhesive interactions.
(12 Dec 1998)
antigen presentation A cell that carries on its surface antigen bound to MCH Class I or Class II molecules and presents the antigen in this context to T-cells. Includes macrophages, endothelium, dendritic cells and Langerhans cells of the skin.
See: MHC restriction, histocompatibility antigens.
(18 Nov 1997)
antigen presenting cell A cell that carries on its surface antigen bound to MCH Class I or Class II molecules and presents the antigen in this context to T-cells. Includes macrophages, endothelium, dendritic cells and Langerhans cells of the skin.
See: MHC restriction, histocompatibility antigens.
(18 Nov 1997)
antigen-presenting cells Immunocompetent cells, usually ia positive, that mediate the cellular immune response by processing and presenting antigens or mitogens which stimulate T-cell activation.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á